Biodexa Pharmaceticals (NASDAQ:BDRX) — Market Cap & Net Worth
Market Cap & Net Worth: Biodexa Pharmaceticals (BDRX)
Biodexa Pharmaceticals (NASDAQ:BDRX) has a market capitalization of $1.95 Million ($1.95 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29987 globally and #6029 in its home market, demonstrating a -2.90% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biodexa Pharmaceticals's stock price $3.01 by its total outstanding shares 648314 (648.31K). Review BDRX current and long-term liabilities to assess the company's total debt and financial obligations.
Biodexa Pharmaceticals Market Cap History: 2015 to 2026
Biodexa Pharmaceticals's market capitalization history from 2015 to 2026. Data shows change from $648.31 Billion to $1.95 Million (-70.09% CAGR).
Index Memberships
Biodexa Pharmaceticals is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #888 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #2819 of 3165 |
Weight: Biodexa Pharmaceticals's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Biodexa Pharmaceticals Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biodexa Pharmaceticals's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
114.01x
Biodexa Pharmaceticals's market cap is 114.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $648.31 Billion | $1.32 Million | -$6.16 Million | 490033.26x | N/A |
| 2017 | $648.31 Billion | $989.00K | -$11.71 Million | 655524.77x | N/A |
| 2018 | $200.98 Billion | $1.94 Million | -$10.37 Million | 103703.48x | N/A |
| 2019 | $89.38 Billion | $674.00K | -$10.09 Million | 132606.18x | N/A |
| 2020 | $48.49 Billion | $343.00K | -$22.19 Million | 141381.60x | N/A |
| 2021 | $27.23 Billion | $578.00K | -$5.46 Million | 47109.32x | N/A |
| 2022 | $5.11 Billion | $699.00K | -$7.66 Million | 7308.60x | N/A |
| 2023 | $43.44 Million | $381.00K | -$7.08 Million | 114.01x | N/A |
Competitor Companies of BDRX by Market Capitalization
Companies near Biodexa Pharmaceticals in the global market cap rankings as of June 18, 2026.
Key companies related to Biodexa Pharmaceticals by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Biodexa Pharmaceticals Historical Marketcap From 2015 to 2026
Between 2015 and today, Biodexa Pharmaceticals's market cap moved from $648.31 Billion to $ 1.95 Million, with a yearly change of -70.09%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.95 Million | +32.60% |
| 2025 | $1.47 Million | -43.95% |
| 2024 | $2.63 Million | -93.96% |
| 2023 | $43.44 Million | -99.15% |
| 2022 | $5.11 Billion | -81.24% |
| 2021 | $27.23 Billion | -43.85% |
| 2020 | $48.49 Billion | -45.74% |
| 2019 | $89.38 Billion | -55.53% |
| 2018 | $200.98 Billion | -69.00% |
| 2017 | $648.31 Billion | 0.00% |
| 2016 | $648.31 Billion | 0.00% |
| 2015 | $648.31 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Biodexa Pharmaceticals was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.95 Million USD |
| MoneyControl | $1.95 Million USD |
| MarketWatch | $1.95 Million USD |
| marketcap.company | $1.95 Million USD |
| Reuters | $1.95 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biodexa Pharmaceticals
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment … Read more